Clinical Trials Logo

Stage III Colorectal Cancer clinical trials

View clinical trials related to Stage III Colorectal Cancer.

Filter by:

NCT ID: NCT04007770 Active, not recruiting - Gynecologic Cancer Clinical Trials

Acupuncture Pilot Study for Cancer-related Cognitive Function

Start date: July 1, 2019
Phase: Phase 2
Study type: Interventional

This study is being done to explore whether acupuncture can improve cognitive difficulties in patients diagnosed with cancer.

NCT ID: NCT03368963 Recruiting - Clinical trials for Gastric Adenocarcinoma

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Start date: January 30, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have spread to other places in the body (metastatic) or cannot be removed by surgery. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102 and nanoliposomal irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT03127111 Not yet recruiting - Clinical trials for Stage III Colorectal Cancer

Genetic and Epigenetic Determinants of Response to Fluorouracil-based Adjuvant Chemotherapy in Patients With Stage III Colorectal Cancer

Start date: December 1, 2022
Phase:
Study type: Observational

The goal of this laboratory research is to look for genetic and epigenetic markers that can predict which patients with stage III colorectal cancer will benefit from fluorouracil-based adjuvant chemotherapy.

NCT ID: NCT03112668 Completed - Clinical trials for Stage IV Breast Cancer

Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners

Start date: December 6, 2017
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well acceptance and commitment therapy works in improving well-being in patients with stage III-IV cancer and their partners. Learning how to accept negative thoughts and feelings and how to live in the present without worrying about the future or past may improve coping skills in patients with stage III-IV cancer and their partners.

NCT ID: NCT03095781 Completed - Clinical trials for Colorectal Adenocarcinoma

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

Start date: July 7, 2017
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the side effects and best dose of Hsp90 inhibitor XL888 when given together with pembrolizumab in treating patients with advanced gastrointestinal cancer that has spread to other places in the body. XL888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving XL888 with pembrolizumab may work better in treating patients with gastrointestinal cancer.

NCT ID: NCT02842203 Active, not recruiting - Clinical trials for Stage III Colorectal Cancer

Use of ctDNA for Monitoring of Stage III Colorectal Cancer

Start date: September 2016
Phase:
Study type: Observational

This observational study will evaluate circulating tumor DNA (ctDNA) as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer (CRC).

NCT ID: NCT02135887 Recruiting - Neutropenia Clinical Trials

A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer.

MB-6
Start date: November 4, 2013
Phase:
Study type: Observational

This is a randomized, double-blind, placebo-controlled multi-center phaseⅢstudy to evaluate efficacy and safety of oxaliplatin-based chemotherapy plus MB-6(320 mg/capsule, 6 capsules tid) in patients with stage 3 colorectal cancer who underwent surgical excision of their primary tumor.